News & Analysis on Clinical Trial Services & Contract Research And Development
Swiss drugmaker Novartis says that its renin inhibitor drug aliskiren (SPP100), which potentially represents the first in a new class of orally-active drugs for high blood pressure, has shown promising data in a clinical trial.
A technique for neutralising the action of the leptin - providing a means for controlling and better understanding of the function of this protein, including its role in unwanted cell growth - has been developed by researchers at the Hebrew University...
While the Drug Discovery Technology Europe show placed an emphasis on issues surrounding drug research, companies serving the pharma and biotech industries took the opportunity to showcase the latest technologies that are set to prove useful in future...
The US Food and Drug Administration (FDA) is gearing up to publish its final guidance on the submission of pharmacogenomic data alongside drug marketing applications, first disseminated in draft form in 2003, reports Phil Taylor.
Measuring RNA levels in tissues and cells using polymerase chain reaction (PCR) forms the basis of pharmacogenomic and toxicogenomic studies, but US firm Genpathway claims to have come up with a better alternative.